ECCO 2025 in Berlin

..und Sie können auch diesmal tagesaktuell dabei sein: mit unseren Daily Reels!

Dieser bedeutende Kongress bietet uns spannende Einblicke in die neuesten Forschungsergebnisse sowie interessante Vorträge und Poster-Präsentationen aus dem Bereich der chronisch-entzündlichen Darmerkrankungen. Anhand von spannenden, tagesaktuellen Videobeiträgen fassen die Expert:innen Prof. Dr. med. Irina Blumenstein, Prof. Dr. med. Dominik Bettenworth, Prof. Dr. med. Timo Rath und Prof. Dr. med Axel Dignaß die wichtigsten Studien, Daten und Erkenntnisse des jeweiligen Kongresstages zusammen und ordnen sie hinsichtlich Ihrer Relevanz für den medizinischen Behandlungsalltag ein.

Keine Episode mehr verpassen:

Daily Reels abonnieren

Freuen Sie sich mit uns auf spannende Videobeiträge aus Berlin:

Tag 1, Donnerstag 20. Februar

Shownotes des Tages:
als PDF zum Herunterladen

_{ab 02:05 min}

Bourgonje AR et al. Systemic antibody responses predict the onset of Inflammatory Bowel Disease up to 10 years before diagnosis. OP01; JCC 2025, 19: S1, i1–i3

_{ab 05:27 min}

Aharoni Frutkoff Y et al. Tasty & Healthy Flexible Diet Induces clinical and biological Remission in Children and Young Adults with Mild-Moderate Crohn's Disease similar to EEN: results from the "TASTI-MM" randomized, physician-blinded, controlled trial. OP 02; JCC 2025, 19: S1, i4.

_{ab 09:20 min}

Arranz EM et al. Chromoendoscopy versus second generation Narrow band Imaging for dysplasia detection in IBD. A prospective randomized controlled trial. DOP003; JCC 2025, 19 : S1, i87–i88

_{ab 13:50 min}

Jairath V et al. Change in Histological inflammation in patients with ulcerative colitis treated with vedolizumab: Results from the continuing VERDICT trial. DOP007; JCC 2025, 19: S1, i92–i93.

Tag 2, Donnerstag 21. Februar

Shownotes des Tages:
als PDF zum Herunterladen

_{ab 02:13 min}

Li Wai Suen C et al. Early serum and faecal cytokines predict clinical outcomes in Acute Severe Ulcerative Colitis: results from PREDICT-UC. DOP057; JCC 2025, 19: S1, i194.

_{ab 06:45 min}

Oldenburg L et al. Higher clinical remission and endoscopic response with vedolizumab in early versus late Crohn’s disease: data from the LOVE-CD trial. DOP085; JCC 2025, 19: S1, i238–i239.

Lenfant M et al. Vedolizumab is more effective at inducing histo-endoscopic healing in early Crohn’s Disease compared to late CD, with comparable healing rates regardless of disease location: data from the LOVE-CD trial. DOP049; JCC 2025, 19: S1, i175–i177.

_{ab 10:45 min}

Jairath V et al. Target achievement after 48 weeks of vedolizumab treatment in patients with moderate to severe Ulcerative Colitis: An interim analysis from the VERDICT trial. DOP050; JCC 2025, 19: S1, i180–i181.

Jairath V et al. Improvement in biomarkers in patients with ulcerative colitis treated with vedolizumab: Results from the continuing VERDICT trial. DOP094; JCC 2025, 19: S1, i252–i253.

_{ab 12:02 min}

L. Peyrin-Biroulet et al. Efficacy and safety of subcutaneous guselkumab induction therapy in patients with Ulcerative Colitis: Results through week 12 from the phase 3 ASTRO study. OP10; JCC 2025, 19: S1, i19–i20

_{ab 14:41 min}

Radia C et al. Higher neoplasia detection rate and lower number of targeted biopsies associated with virtual chromoendoscopy in IBD surveillance: a real-world, multicentre UK study. OP13; JCC 2025, 19 : S1, i27–i28.

_{ab 16:25 min}

Kusumam K et al. EndoUC: an AI-assisted endoscopic Ulcerative Colitis activity grading application for deployment in clinical Trials. DOP077; JCC 2025, 19: S1, i224–i226

Tag 3, Donnerstag 22. Februar

Shownotes des Tages:
als PDF zum Herunterladen

_{ab 02:40 min}

Bouguen G et al. Comparative efficacy of infliximab and vedolizumab after failure of a first anti-TNF in patients with ulcerative colitis: a double-blind randomized controlled trial (EFFICACI). OP38; JCC 2025, 19: S1, i74.

_{ab 06:05 min}

Hart A et al. Efficacy and safety of subcutaneous guselkumab induction therapy in patients with moderately to severely active Crohn’s disease: Results through Week 48 from the phase 3 GRAVITI study. OP33; JCC 2025, 19: S1, i66–i67.

_{ab 09:02 min}

Jairath V et al. Treatment with RO7790121 induces and maintains histologic and histologic-endoscopic improvement and remission in moderately to severely active ulcerative colitis – Results from TUSCANY-2. OP39; JCC 2025, 19: S1, i75–i76.

_{ab 12:31 min}

Jairath V et al. Phase 1b study of SOR102, a novel, orally delivered bispecific anti-TNF/anti-IL-23 domain antibody in patients with mild to severe ulcerative colitis. OP31; JCC 2025, 19: S1, i62–i63.

Daily Reels 2024 verpasst?

Sie haben die drei Folgen der Daily Reels zur UEGW 2024 aus Wien verpasst? Kein Problem: Sie können die Videobeiträge sowie die Shownotes der einzelnen Tage jederzeit unter dem folgenden Link aufrufen:

Daily Reels der UEGW 2024 (intern)